Pharmaceuticals

Healthcare

16 April, 2024

ChrysCapital invests in Gujarat-based pharma player La Renon Healthcare

Homegrown private equity player ChrysCapital has widened its healthcare portfolio in the country with a $70 million (Rs 585 crore) ......

Premium

Healthcare

10 April, 2024

KKR-controlled JB Chemicals draws interest from PE firms, drugmakers

A clutch of suitors including pharmaceutical companies and bulge-bracket private equity firms have shown interest in picking up a majority ......

Healthcare

14 March, 2024

ChrysCap-backed Eris Life acquires Biocon Biologics' India formulations business

Eris Lifesciences, a Mumbai-based listed pharmaceutical company backed by private equity firm ChrysCapital and Kuwait Investment Authority, is to acquire ......

Healthcare

01 March, 2024

Advent to merge Cohance, Suven in share-swap deal

Advent International, a global private equity firm, Thursday announced the plan to merge two of its pharmaceutical portfolio companies, Cohance ......

Premium

Healthcare

29 February, 2024

Former Biocon execs' CRAMS firm Anthem Bio eyes pre-IPO funding

Bengaluru-based pharma contract research company Anthem Biosciences Pvt. Ltd, which hit the billion-dollar valuation mark two years ago after private ......

Healthcare

13 February, 2024

ChrysCapital-backed Eris Life acquires controlling stake in Swiss Parenterals for $77 mn

Listed pharmaceuticals player Eris Lifesciences Ltd has acquired 51% stake in sterile injectables company Swiss Parenterals for Rs 637.5 crore ......

Healthcare

12 February, 2024

Manipal Hospitals backer Novo Holdings to invest $35 bn over next six years

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest about $35 billion by 2030, CEO ......

Premium

Healthcare

25 January, 2024

Bottomline: Affirma-backed nutraceuticals maker Tirupati's financial see-saw continues

Nutraceuticals maker Tirupati Medicare recorded a hit in operational margin in FY23 after fluctuations last fiscal, even as the company’s ......

Premium

Healthcare

19 January, 2024

Bottomline: InvAscent-backed Symbiotec has struggled to break out; will FY25 be different?

Homegrown corticosteroid and hormones API-maker Symbiotec Lifesciences Pvt. Ltd’s revenue and profitability took a hit in FY23, even as the ......

Premium

Healthcare

03 January, 2024

Kotak's second special situations PE fund bankrolling big-ticket pharma acquisition

Kotak Alternate Asset Managers (previously Kotak Investment Advisors), the alternative investment arm of Kotak Group, which hit a first close of ......